Agomab Raises $200M in 12.5M‐Share IPO at $16 Per ADS
Agomab raised approximately $200 million gross by selling 12.5 million American Depositary Shares at $16 each in its IPO. These ADS began trading on the Nasdaq Global Select Market on February 6, 2026.
1. Initial Public Offering Closure
Agomab completed its initial public offering of 12,500,000 American Depositary Shares at $16 per ADS, generating approximately $200.0 million in gross proceeds before underwriting discounts, commissions and expenses.
2. Nasdaq Listing Details
The ADS began trading on the Nasdaq Global Select Market on February 6, 2026, following SEC registration effectiveness on January 30, 2026, marking Agomab’s transition to a publicly traded company.
3. Strategic Use of Proceeds
Proceeds from the offering are earmarked to advance Agomab’s clinical-stage pipeline focused on chronic fibrotic and immunology indications, fund ongoing trials and support broader research and development efforts.